Telomeres and atherosclerosis

Cardiovascular Journal of Africa

Volumn 23, Issue 10, 2012, Pages 563-571

  Khan, Sajidah ^a   Chuturgoon, Anil A ^a   Naidoo, Datshana P ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Coronary artery disease; Molecular and cellular cardiology

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESISTIN; SOMATOMEDIN B; STATIN (PROTEIN); TELOMERASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; XANTHINE OXIDASE;

AGING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL PROLIFERATION; CELL SURVIVAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA DAMAGE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EXERCISE; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INJURY; INSULIN RESISTANCE; LEUKOCYTE; NONHUMAN; OBESITY; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PULSE PRESSURE; SENESCENCE; SMOKING; STEM CELL; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL AGING; ENDOTHELIUM, VASCULAR; HUMANS; PROGNOSIS; RISK FACTORS; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING;

EID: 84874068224     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2012-056     Document Type: Article

References (126)

1. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241
2. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res 2007; 100: 15-26.
3. Minamino T, Miyauchi H, Yoshida T, Ishida YHY, Komuro I. Endothelial cell senescence in human atherosclerosis. Role of telomere in endothelial dysfunction. Circulation 2002; 105: 1541-1544.
4. Serrano AL, Andres V. Telomeres and cardiovascular disease - Does size matter? Circ Res 2004; 94: 575-584.
5. Burrig KF. The endothelium of advanced atherosclerotic plaques in humans. Arterioscler Thromb 1991; 11: 1678-1689.
6. Ross R, Wight TN, Strandness E, Thiele B. Human atherosclerosis. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. Am J Pathol 1984; 114: 79-93.
7. Willeit P, Willeit J, Brandstatter A, Ehrlenbach S, et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2010; 30: 1649-1656.
8. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-573.
9. Verdun RE, Karlseder J. Replication and protection of telomeres. Nature 2007; 447: 924-931.
10. Blackburn EH. Switching and signalling at the telomere. Cell 2001; 106: 661-673.
11. Edo MD, Andres V. Aging, telomeres and atherosclerosis. Cardiovasc Res 2005; 66: 213-221.
12. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005; 26(5): 867-874.
13. Blasco MA. Telomeres and cancer: a tale with many endings. Cur Opin Genet Develop 2003; 13: 70-76.
14. Lin KW. Telomeres, telomerase and tumorigenesis - A review. Medscape Gen Med 2004; 6(3):19.
15. Samassekou O, Gadji M, Drouin R, Yan J. Sizing the ends: normal length of human telomeres. Ann Anat 2010; 192: 284-291
16. Brouilette SW, Whittaker A, Stevens SE, van der Harst P, et al. Telomere length is shorter in healthy offspring of subjects with coronary artery disease: support for the telomere hypothesis. Heart 2008; 94: 422-425.
17. Dei Cas A, Spigoni V, Franzini L, Preti M, et al. Lower endothelial progenitor cell number, family history of cardiovascular disease and reduced HDL-cholesterol levels are associated with shorter leukocyte telomere length in healthy young adults. Nutr Metabol Cardiovasc Dis. doi.org/10.1016/j.numecd. 2011.04.005.
18. Fuster JJ, Andres V. Telomere biology and cardiovascular disease. Circ Res 2006; 99: 1167-1180.
19. Valdes AM, Andrew T, Gardner JP, Kimura M, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005; 366: 662-664.
20. Morla M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti AGN. Telomere shortening in smokers with and without COPD. Eur Respir J 2006; 27: 525-528.
21. Demissie S, Levy D, Benjamin EJ, Cupples LA, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell 2006; 5: 325-330.
22. Gardner JP, Shengxu L, Srinivasan SR, Wei C, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation 2005; 111: 2171-2177.
23. Adaikalakoteswari A, Balasubramanyam M, Mohan V. Telomere shortening occurs in Asian Indian Type 2 diabetic patients. Diabet Med 2005; 22: 1151-1156.
24. Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care 2006; 29: 283-289.
25. Zee RL, Castonguay AJ, Barton NS, Germer S, Martin M. Mean leucocyte telomere length shortening and type 2 diabetes mellitus : a case-control study. Translational Res 2010; 155: 166-169.
26. Salpea KD, Talmud PJ, Cooper JA, Maubaret CG, Stephens JW, Abelak K, Humphries SE. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis 2010; 209; 42-50.
27. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
28. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, et al. Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study. Diabetologia 2005; 48: 2519-2524.
29. Seedat YK. Ethnicity, hypertension, coronary heart disease and renal diseases in South Africa. Ethn Hlth 1996; 1(4): 349-57.
30. Motala AA, Pirie FJ, Gouws E, Amod A, Omar MA. High incidence of type 2 diabetes mellitus in South African Indians: a 10-year follow-up study. Diabet Med 2003; 20: 23-30.
31. Stewart JA, Chaiken MF, Wang F, Price CM. Maintaining the end: Role of telomere proteins in end-protection, telomere replication and length regulation. Mutat Res: Fundam Mol Mech Mutagen 2011,doi:10.1016/j. mrfmmm.2011.08.011.
32. Palm W, de Lange T. How shelterin protects mammalian telomeres. A Rev Genet 2008; 42: 301-334.
33. Blasco MA, et al. Mammalian telomeres and telomerase: why they matter for cancer and aging. Eur J Cell Biol 2003; 82: 441-446.
34. Oeseburg H, de Boer RA., van Gilst WH, van der Harst P. Telomere biology in healthy aging and disease. Pflugers Arch 2010; 459(2): 259-268.
35. Gilson E, Segal-Bendirdjian E. The telomere story or the triumph of an open-minded research. Biochimie 2010; 92: 321-326.
36. Saliques S, Zeller M, Lorin J, Lorgis L. et al. Telomere length and cardiovascular disease. Arch Cardiovasc Dis 2010; 103: 454-459.
37. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14: 4240-4248.
38. Chen W, Gardner JP, et al. Leukocyte telomere length is associated with HDL cholesterol levels: The Bogalusa heart study. Atherosclerosis 2009; 205(2): 620-625.
39. Von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002; 27: 339-344.
40. De Meyer T, Rietzschel ER, De Buyzere ML, et al. Systemic telomere length and preclinical atherosclerosis: the Asklepios Study. Eur Heart J 2009; 30: 3074-3081.
41. Aviv A. Genetics of leukocyte telomere length and its role in atherosclerosis. Mutat Res: Fundam Mol Mech Mutagen 2012; 730: 68-74.
42. De Meyer T, Rietzschel ER, de Buyzere ML, van Criekinge W, Bekaert S. Telomere length and cardiovascular ageing: The means to the ends? Ageing Res Rev 2011; 10: 297-303.
43. Hunt SC, Chen W, Gardner JP, Kimura M, Srinivasan SR, Eckfeldt JH, et al. Leukocyte telomeres are longer in African Americans than whites: the National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study. Aging Cell 2008; 7: 451-458.
44. Zhu H, Wang X, Gutin B, Davis CL, Keeton D, Thomas J, et al. Leukocyte telomere length in healthy Caucasian and African-American adolescents: relationhips with race, sex, adiposity, adipokines and physical activity. J Pediatr 2011; 158: 215-220.
45. Nawrot TS, Staessen JA, Gardner JP, Aviv A. Telomere length and possible link to X chromosome. Lancet 2004; 363: 507-510.
46. Von Zglinicki T, Burkle A, Kirkwood TB. Stress, DNA damage and aging: an integrative approach. Exp Gerontol 2001; 36: 1049-1062.
47. Kawanishi S, Oikawa S. Mechanism of telomere shortening by oxidative stress. Ann NY Acad Sci 2004; 1019: 278-284.
48. Heineke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis. Atherosclerosis 1998: 141: 1-5.
49. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res 2000; 87: 840-844.
50. Griendling KK, Sorescu D, et al. NADPH oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
51. Sandau K, Pfeilschifter J, et al. The balance between nitric oxide and superoxide determines apoptotic and necrotic death of rat mesangial cells. J Immunol 1997; 158: 4938-4946.
52. Brune B, von Knethen A, et al. Nitric oxide: an effector of apoptosis. Cell Death Differ 1999; 6: 969-975.
53. Vasa M, Breitschopf K, Zeiher AM, Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res 2000; 87: 540-542.
54. De la Fuente M, Miquel J. An update of the oxidation-inflammation theory of aging: the involvement of the immune system in oxi-inflammaging. Curr Pharm Des 2009; 15: 3003-3026.
55. Floyd RA, Hensley K, Jaffery F, Maidt L, Robinson K, Pye Q, Stewart C. Increased oxidative stress brought on by pro-inflammatory cytokines in neuro-degenerative processes and the protective role of nitrone-based free radical traps. Life Sci 1999; 65: 1893-1899.
56. Rahman I, Gilmour PS, Jimenez LA, MacNee W. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem 2002; 234-235: 239-248.
57. Beyne-Rauzy O, Prade-Houdellier N, Demur C, Recher C, Aye J, Laurent G, Mansat-De Mas V. Tumour necrosis factor alpha inhibits h-TERT gene expression in human myeloid normal and leukemic cells. Blood 2005; 106: 3200-3205.
58. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
59. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000; 28: 1708-1716.
60. Klouche M, Gottschling V, et al. Atherogenic properties of enzymatically degraded LDL - selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1376-1385.
61. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101: 2889-2895.
62. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal 2011; 23: 1515-1527.
63. Breitschopf K, Zeiher AM, Dimmeler S. Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism. FEBS Lett 2001; 493: 21-25.
64. Miyauchi H, Minamino T, Tateno K, et al. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J 2004; 23: 212-220.
65. Rosso A, Balsamo A, Gambino R, Dentelli P, et al. p53 mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. J Biol Chem 2006; 281(7): 4339-4347.
66. Minamino T, Komuro I. Vascular cell senescence in human atherosclerosis. Int Congress Ser 2004; 1262: 566-569.
67. Houben JMJ, Moonen HJJ, van Schooten FJ, Hageman GJ. Telomere length assessment: Biomarker of chronic oxidative stress? Free Rad Biol Med 2008; 44: 235-246.
68. Kawanishi S, Hiraku Y, Oikawa S. Mechanism of guanine-specific DNA damage by oxidative stress and its role in carcinogenesis and aging. Mutat Res 2001; 488: 65-76.
69. Oikawa S, Kawanishi S. Site-specific DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening. FEBS Lett 1999; 453: 365-368.
70. Von Zglinicki T, Pilger R, Sitte N. Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Rad Biol Med 2000; 28(1): 64-74.
71. Petersen S, Saretzki G, von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp Cell Res 1998; 239: 152-160.
72. Wilson WR, Herbert KE, Mistry Y, et al. Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease. Eur Heart J 2008; 29: 2689-94.
73. Burke A, Fitzgerald GA. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis 2003; 46: 79-90.
74. Jeanclos E, Schork NJ, Kyvik KO, Kimura M, Skurnick JH, Aviv A. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension 2000; 36: 195-200.
75. Benetos A., Gardner JP, Zureik M, Labat C, Xiaobin L, Adamopoulos C, et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 2004; 43: 182-185.
76. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue. Clin Endocrinol 2006; 64(4): 355-365.
77. Yudkin JS, Kumari M, et al. Inflammation, obesity, stress and coronary artery disease. Atherosclerosis 2000; 148: 209-214.
78. Baik I, Ascherio A, et al. Adiposity and mortality in men. Am J Epidemiol 2000; 152: 264-271.
79. Rexode KM, Carey VJ, et al. Abdominal adiposity and coronary heart disease in women. J Am Med Assoc 1998; 280: 1843-1848.
80. Beltowski I, Wojcicka G, Jamroz A. Leptin decreases plasma paraxonases 1 (PON 1) activity and induces oxidative stress: the possible novel mechanism for pro-atherogenic effect of chronic hyperleptinaemia. Atherosclerosis 2003; 170: 21-29.
81. Nordfjall I, Elliasson M, Stegmayr B, et al. Telomere length is associated with obesity parameters but with a gender difference. Obesity 2008; 16: 2682-2689.
82. De Fronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard lecture 2009. Diabetologia 2009; 53: 1270-1287.
83. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycaemia and atherosclerosis. Cell Metab 2011; 14: 575-558.
84. Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001; 86: 972-979.
85. Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H, Komuro I. Akt negatively regulates the in-vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J 2004; 23: 212-220.
86. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
87. Basta G, Schmidt AM, DeCaterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovas Res 2004; 63: 582-592.
88. Wendt T, Bucciarelli L, Quet W, et al. Receptor for advanced glycation end products (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002; 4: 228-237.
89. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
90. Mokini Z, Loredana Marcovscchio M, Chiarelli F. Molecular pathology of oxidative stress in diabetic angiopathy: Role of mitochondrial and cellular pathways. Diabetes Res Clin Pract 2010; 87: 313-321.
91. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycaemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072.
92. Su Y, Liu XM, Sun YM, et al. The relationship between endothelial dysfunction and oxidative stress in diabetes and pre-diabetes. Int J Clin Pract 2008; 62: 877-882.
93. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense HDL particles displaying impaired anti-oxidative activity. J Clin Endocrinol Metab 2004; 89: 4963-4971.
94. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial super-oxide production blocks 3 pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
95. Brodsky SV, Gealekman O, Chen J, Zhang F, et al. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res 2004; 94: 377-384.
96. Rosso A, Balsamo A, Gambino R, Dentelli P, et al. p53 Mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. J Biol Chem 2006; 281: 4339-4347.
97. Satoh M, Ishikawa Y, Takahashi Y, Itoh T, Minami Y, Nakamura M. Association between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease. Atherosclerosis 2008; 198: 347-353.
98. Adaikalakoteswari A, Balasubramanyam M, Ravikumar R, Deepa R, Mohan V. Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy. Atherosclerosis 2007; 195: 83-89.
99. Olivieri F, Lorenzi M, Antonicelli R, et al. Leukocyte telomere shortening in elderly Type2DM patients with previous myocardial infarction. Atherosclerosis 2009; 206: 588-593.
100. Salpea KD, Humphries SE. Telomere length in atherosclerosis and diabetes. Atherosclerosis 2010; 209(1): 35-38.
101. Ogami M, Ikura Y, Ohsawa M, Matsuo T, et al. Arterioscler Thromb Vasc Biol 2004; 24: 546-550.
102. Chang E, Harley CB. Telomere length and replicative ageing in human vascular tissues. Proc Natl Acad Sci USA 1995; 92: 11190-11194.
103. Okuda I, Khan MY, Skurnick J, Kimura M, Aviv H, Aviv A. Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis 2000; 152: 391-398.
104. Samani NJ, van der Harst P. Biological ageing and cardiovascular disease. Heart 2008; 9(5): 537-539.
105. Butt HZ, Atturu GNJ, London NJ, Sayers RD, Bown MJ. Telomere length dynamics in vascular disease: A review. Eur J Vasc Endovasc Surg 2010; 40: 17-26.
106. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet 2001; 358: 472-473.
107. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 2003; 23: 842-846.
108. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Asociation between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003; 361: 393-395.
109. Brouilette SW, Moore JS, McMahon AD, et al. Telomere length, risk of coronary disease and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369: 107-114.
110. Fitzpatrick AL, Kronmal RA, Gardner JP, et al. Leukocyte telomere length and cardiovascular disease in the Cardiovascular Health Study. Am J Epidemiol 2007; 165: 14-21.
111. Farzaneh-Far R, Cawthon R, Na B, et al. Prognostic value of leucocyte telomere length in patients with stable coronary artery disease. Data from the Heart and Soul Study. Arterioscler Thromb Vasc Biol 2008; 28: 1379-1384.
112. Zee RYL, Michaud SE, Germer S, Ridker PM. Association of shorter mean telomere length with risk of incident myocardial infarction: A prospective, nested case-control approach. Clin Chim Acta 2009; 403: 139-141.
113. Ligi P. Diet, nutrition and telomere length. J Nutr Biochem 2011; 22: 895-901.
114. Zhu H, Belcher M, van der Harst P. Healthy aging and disease: role for telomere biology? Clin Sci 2011; 120: 427-440.
115. La Rocca TJ, Seals DR, Pierce GL. Leukocyte telomere length is preserved with aging in endurance exercise-trained adults and related to maximal aerobic capacity. Mechan Ageing Develop 2010; 131: 165-167.
116. Tarkanyi I, Aradi J. Pharmacological intervention strategies for affecting telomerase activity : Future prospects to treat cancer and degenerative disease. Biochimie 2008; 90: 156-172.
117. Xia L, Wang XX, Hu XS, et al. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. Br J Pharmacol 2008; 155: 387-394.
118. Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. J Am Med Assoc 2010; 303(3): 250-257.
119. Bode-Boger SM, Martens-Lobenhoffer J, Tager M, Schroder H, Scalera F. Aspirin reduces endothelial cell senescence. Biochem Biophys Res Commun 2005; 334: 1226-1232.
120. Donnini S, Terzuoli E, Ziche M, Morbidelli L. Sulfhydryl angiotensinconverting enzyme inhibitor promotes endothelial cell survival through nitric-oxide synthase, fibroblast growth factor-2, and telomerase crosstalk. J Pharmacol Exp Ther 2010 332; 3: 776-784.
121. Spyridopoulos I, Haendeler J, Urbich C, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004; 110: 3136-3142.
122. Satoh M, Minami Y, Takahashi Y, et al. Effect of intensive lipidlowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease. Clin Sci 2009; 116: 827-835.
123. Saliques S, Teyssier J-R, Vergely C, Lorgis L, et al. Circulating leucocyte telomere length and oxidative stress : A new target for statin therapy. Atherosclerosis 2011, doi:10.1016/j.atherosclerosis.2011.09.011.
124. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30: e47.
125. Kimura M, Stone RC, Hunt SC, Skurnick J, Lu X, Cao X, Harley CB, Aviv A. Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths. Nature Protocols 2010; 5(9): 1596-1607.
126. Huzen J, van Veldhuisen DJ, van Gilst WH, van der Harst P. Telomeres and biological ageing in cardiovascular disease. Ned Tijdschr Geneeskd 2008; 152: 1265-1270.